Business Context and Reporting Period
This Form 10-Q covers the three months ended March 31, 2021, and was filed May 12, 2021. The filing identifies the registrant as EyeGate Pharmaceuticals, Inc., although the request metadata identifies Kiora Pharmaceuticals, Inc.; investors should verify the issuer and filing identity.
EyeGate is a clinical-stage pharmaceutical company developing ophthalmic and systemic products for inflammatory and immune diseases. Its principal programs are PP-001, acquired through the December 2020 Panoptes acquisition, and Ocular Bandage Gel (OBG), which is being developed for ocular-surface conditions.
Financial Results and Liquidity
| Metric | Q1 2021 | Q1 2020 | Change |
|---|---|---|---|
| Revenue | No clear revenue value reported in the presented statements | No clear revenue value reported in the presented statements | Not determinable |
| Research and development expense | $1.280 million | $0.938 million | +$0.342 million |
| General and administrative expense | $1.300 million | $1.033 million | +$0.268 million |
| Total operating expenses | $2.580 million | $1.971 million | +$0.610 million |
| Net loss | $2.581 million | $1.952 million | +$0.629 million loss |
| Net loss per share | $0.37 | $0.43 | Loss per share improved due to higher share count |
| Cash used in operating activities | $2.570 million | $2.400 million | +$0.170 million use |
| Cash and cash equivalents at period end | $6.610 million | Not provided in the filing excerpt for comparison | Not determinable |
Gross and operating margins are not meaningful because the company is clinical-stage and reported no clear product revenue value in the presented income statement. Comprehensive loss was $2.570 million. Stock-based compensation was $0.217 million.
Total assets were $20.621 million and total liabilities were $7.936 million at March 31, 2021. The company had $5.343 million of contingent consideration, a $0.278 million PPP loan recorded at quarter-end, and no other indebtedness. The PPP loan was forgiven in full in April 2021.
Financing activities generated $8.039 million, including approximately $7.989 million of net proceeds from a January private placement and $0.050 million from warrant exercises. Common shares outstanding increased to 7,097,912 from 5,556,394 at December 31, 2020.
Material Changes Versus the Prior Comparable Period
- R&D expense increased 36%, primarily from Panoptes-related personnel costs, OBG manufacturing costs, and PP-001 development, partly offset by lower OBG clinical activity and the expiration of a prepaid research agreement.
- G&A expense increased 26%, including approximately $0.050 million of Panoptes acquisition-related costs and higher professional and corporate expenses.
- Net loss increased 32% to $2.581 million, while operating cash usage increased 7%.
- The January 2021 private placement materially strengthened cash balances but increased potential dilution through 1,531,101 shares issued and warrants for an additional 1,531,101 shares.
- The OBG development strategy shifted from a medical device pathway to a drug pathway following a first-quarter FDA Type-B meeting, potentially enabling Medicare Part D reimbursement.
- The Panoptes acquisition contributed approximately $0.439 million of net loss in the quarter and added PP-001, goodwill, in-process R&D, and contingent obligations.
Guidance, Outlook, Risks, and Unusual Items
- Management expects significant expenses and increasing operating losses as PP-001, OBG, and other candidates advance through clinical development. The company does not expect product candidates to be commercially available, if at all, for several years.
- Based on March 31 cash, management expects funding for planned operations through August 31, 2021, subject to changes in spending. Additional capital will be required through equity or debt financing, licensing, collaborations, or grants.
- Management states that recurring losses and the need for additional financing create substantial doubt about the company’s ability to continue as a going concern. No committed external funding source exists.
- Potential financing may dilute existing shareholders or require unfavorable terms; failure to obtain funding could delay, reduce, or terminate development and commercialization activities.
- Clinical, regulatory, manufacturing, intellectual-property, competition, and market-acceptance risks remain significant. COVID-19 could disrupt clinical studies and capital access, although no material adverse operational impact had occurred as of the report date.
- Contingent consideration includes milestone-related obligations associated with the Panoptes and Jade acquisitions. Additional OBG licensing milestones of up to $4.750 million may become payable, and Panoptes-related earn-outs could be material if development and regulatory milestones are achieved.
- The company reported no material legal proceedings, no material off-balance-sheet arrangements, and no material changes to previously disclosed risk factors.
Important Facts for Investors to Verify
- Confirm the issuer discrepancy: the supplied metadata says Kiora Pharmaceuticals, while the filing text identifies EyeGate Pharmaceuticals, Inc. and ticker EYEG.
- Verify the company’s post-quarter liquidity and financing status, particularly given the stated cash runway only through August 31, 2021.
- Review the terms, exercise conditions, and potential dilution from the 4.247 million outstanding warrants and 0.370 million stock options at March 31, 2021.
- Track FDA and clinical-development progress for PP-001 and OBG, including the consequences of OBG’s transition to a drug pathway.
- Assess the probability and timing of Panoptes, Jade, and SentrX milestone payments and their effect on future cash requirements.
- Reconcile any reported collaboration or grant revenue with the income statement, because the presented statements do not provide a clear revenue line-item value.